泰凌医药(01011)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01011 泰凌医药

休市中 10-30 13:18:33

0.245

-0.020

-7.55%

最高0.350	最低0.211	成交量16.10万
今开0.290	昨收0.265	日振幅52.45%
总市值4.40亿	流通市值4.40亿	总股本17.97亿
成交额4.12万	换手率0.01%	流通股本17.97亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01011","market":"HK","secType":"STK","nameCN":"泰凌医药","latestPrice":0.245,"timestamp":1793337513076,"preClose":0.265,"halted":0,"volume":161000,"delay":0,"changeRate":-0.07547169811320761,"floatShares":1797000000,"shares":1797000000,"eps":-0.04221,"marketStatus":"休市中","change":-0.02,"latestTime":"10-30 13:18:33","open":0.29,"high":0.35,"low":0.211,"amount":41190,"amplitude":0.524528,"askPrice":0.255,"askSize":10000,"bidPrice":0.23,"bidSize":10000,"shortable":0,"etf":0,"ttmEps":-0.018,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1793583000000},"marketStatusCode":7,"adr":0,"listingDate":1303228800000,"exchange":"SEHK","adjPreClose":0.265,"openAndCloseTimeList":[[1793323800000,1793332800000],[1793336400000,1793347200000]],"volumeRatio":0.6747694887122703,"lotSize":10000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01011/tweets","defaultTab":"tweets","newsList":[{"id":"1146874259","title":"泰凌医药(01011)申请撤销9,200万元仲裁裁决并诉求康辰强制回购25.3%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=1146874259","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146874259?lang=zh_cn&edition=full","pubTime":"2026-10-30 20:12","pubTimestamp":1793362322,"startTime":"0","endTime":"0","summary":"香港，2026年10月30日，泰凌医药发布自愿性公告披露公司最新法律进展：一方面，公司已向有管辖权的人民法院申请撤销〔2026〕中国贸仲京裁字第1519号仲裁裁决；另一方面，旗下全资子公司泰凌医药（亚洲）有限公司已就北京康辰生物科技有限公司股权事宜提起诉讼，要求被告强制回购其所持北京康辰约25.3%股权。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679321973","title":"泰凌医药：就第一宗仲裁裁决申请撤销及就北京康辰股权提起诉讼","url":"https://stock-news.laohu8.com/highlight/detail?id=2679321973","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679321973?lang=zh_cn&edition=full","pubTime":"2026-10-30 20:08","pubTimestamp":1793362080,"startTime":"0","endTime":"0","summary":"南财智讯10月30日电，泰凌医药（01011.HK）发布自愿公告，公司就第一宗仲裁裁决向人民法院申请撤销。此前，相关仲裁裁决裁定公司及相关连带方合计须支付违约金、相关费用及仲裁分担款项约人民币9200万元。同时，公司全资附属公司泰凌医药(亚洲)有限公司就北京康辰生物科技有限公司股权提起诉讼，请求法院判令被告强制回购其持有的北京康辰约25.30%的股权。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610303916924890.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610303916924890.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","01011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158107480","title":"泰凌医药2025年度完善对外投资与风险管控，强化公司治理架构","url":"https://stock-news.laohu8.com/highlight/detail?id=1158107480","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158107480?lang=zh_cn&edition=full","pubTime":"2026-10-23 19:42","pubTimestamp":1792755742,"startTime":"0","endTime":"0","summary":"泰凌医药于截至2025年12月31日止年度在对外投资与风险管理方面持续完善机制，并通过多项内部管控和审慎方针加强投资决策效率。董事会作为最高决策机构，负责审批重大投资方案及定期审阅投资组合和风险回报报告；管理层于授权范围内负责日常投资运作与风险监测，并定期向董事会及审核委员会汇报投资组合表现。整体而言，公司在报告期内致力于强化内部治理与投资风险管控，维持稳健经营基石。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"泰凌医药2025年度完善对外投资与风险管控，强化公司治理架构","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100459521","title":"泰凌医药(01011)将于11月9日召开股东特别大会 拟改聘國衛会计师事务所为核数师","url":"https://stock-news.laohu8.com/highlight/detail?id=1100459521","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100459521?lang=zh_cn&edition=full","pubTime":"2026-10-21 07:31","pubTimestamp":1792539069,"startTime":"0","endTime":"0","summary":"泰凌医药10月21日公告，公司拟于2026年11月9日（星期一）上午11时在香港干诺道中168–200号信德中心西座21楼2102室召开股东特别大会。会议将审议并酌情通过以下普通决议案：","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675072556","title":"泰凌医药(01011)存仓市值总计1亿港元 股东将2.51亿股股票存入香港上海汇丰银行","url":"https://stock-news.laohu8.com/highlight/detail?id=2675072556","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675072556?lang=zh_cn&edition=full","pubTime":"2026-10-16 08:10","pubTimestamp":1792109405,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，10月15日，泰凌医药(01011)出现仓位异动，存仓市值总计1亿港元，占比13.96%。该公司股东将2.51亿股股票存入香港上海汇丰银行，持股比例增加13.96%。泰凌医药发布公告，经考虑本公司审核委员会的推荐建议，董事会已议决委任国卫会计师事务所有限公司(国卫)为本公司新核数师，以填补大华马施云退任后的临时空缺，自股东于股东特别大会上批准之日起生效，且其任期将直至本公司下一届股东周年大会结束为止。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1508065.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","LU0348816934.USD","BK4207","LU1282648689.USD","LU0797268264.HKD","LU0634319403.HKD","00005","LU0516422366.SGD","LU0918141887.USD","LU0516422952.EUR","HSBH","HSBC","BK1610","LU0516422440.USD","LU0052756011.USD","LU0211326755.USD","LU2236285917.USD","LU1105468828.SGD","LU1481107354.HKD","LU0164880469.USD","BK1191","03143","BK1572","HSHD.SI","01011","LU1770036033.HKD","LU0516423174.USD","LU0348814723.USD","BK4521","LU0417516738.SGD","LU2449936058.SGD","LU0976567544.SGD","LU1267930227.SGD","LU0348735423.USD","LU0345775950.USD","LU0310800965.SGD","LU0211326839.USD","LU0516423091.SGD","LU2226246903.HKD","BK1601","LU0540923850.HKD","BK4585","HSBA.UK","IE0008369823.USD","LU0918141705.HKD","BK1231","LU0128525689.USD","LU0345776255.USD","LU0149721374.USD","LU0496365809.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138753647","title":"泰凌医药2026年9月股份变动月报表公布，新发行约8.48亿股","url":"https://stock-news.laohu8.com/highlight/detail?id=1138753647","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138753647?lang=zh_cn&edition=full","pubTime":"2026-10-06 17:51","pubTimestamp":1791280281,"startTime":"0","endTime":"0","summary":"2026年10月6日，泰凌医药发布截至2026年9月30日的证券变动月报。报告显示，公司法定/注册股本为62,592,500,000股普通股，面值每股USD 0.0000008，总额维持在USD 50,074；优先股为32,500,000股，面值每股USD 0.0000008，总额维持在USD 26。公司本月底法定/注册股本总额为USD 50,100。公司确认，截至当前月末，各类股份均合法合规地完成发行与变动操作，并符合香港联交所及相关法规要求。公告由执行董事吴铁于2026年10月6日签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136722202","title":"泰凌医药2026年中期财报：营收23.7百万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1136722202","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136722202?lang=zh_cn&edition=full","pubTime":"2026-09-29 16:42","pubTimestamp":1790671320,"startTime":"0","endTime":"0","summary":"泰凌医药发布的2026年中期报告显示，期内实现营收约23.7百万元，相较2025年同期的11.7百万元增加约12.0百万元，同比增幅约97.3%。毛利约6.9百万元，较上年同期的10.0百万元下降约3.1百万元。经营活动所用现金净额约14.3百万元，相比上年同期减少近4.9百万元。成本结构方面，销售及分销开支从上年同期的3.92百万元下降至本期的1.98百万元，一般及行政开支则从6.19百万元增加至6.57百万元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"泰凌医药2026年中期财报：营收23.7百万元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670044074","title":"泰凌医药：附属公司就康辰生物股东知情权事宜申请强制执行","url":"https://stock-news.laohu8.com/highlight/detail?id=2670044074","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670044074?lang=zh_cn&edition=full","pubTime":"2026-09-25 21:10","pubTimestamp":1790341806,"startTime":"0","endTime":"0","summary":"南财智讯9月25日电，泰凌医药（01011.HK）发布自愿公告，公司全资附属公司泰凌医药（亚洲）有限公司持有北京康辰生物科技有限公司约25.30%股权。因康辰方单方面接管康辰生物并阻挠泰凌亚洲行使股东知情权，泰凌亚洲提起股东知情权诉讼并获二审胜诉。因康辰生物拒不履行生效判决，泰凌亚洲已依法向法院申请强制执行并获立案受理。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609253884322395.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609253884322395.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01011","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171587153","title":"泰凌医药（01011）披露附属公司对康辰生物股东知情权纠纷最新进展 已申请法院强制执行","url":"https://stock-news.laohu8.com/highlight/detail?id=1171587153","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1171587153?lang=zh_cn&edition=full","pubTime":"2026-09-25 21:06","pubTimestamp":1790341574,"startTime":"0","endTime":"0","summary":"泰凌医药9月25日发布自愿性公告，通报全资附属公司泰凌医药（亚洲）有限公司与北京康辰生物科技有限公司股东知情权纠纷的最新进展。公告指出，业绩对赌期届满后，自2024年起康辰方单方面接管康辰生物经营管理、修改公司章程，并持续阻挠泰凌亚洲依法行使股东知情权，导致泰凌亚洲无法了解康辰生物的真实财务状况。生效判决后，泰凌亚洲多次要求康辰生物配合查阅，但康辰生物在法定履行期限内拒不提供任何资料。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667666940","title":"泰凌医药(01011)委任国卫为新核数师","url":"https://stock-news.laohu8.com/highlight/detail?id=2667666940","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667666940?lang=zh_cn&edition=full","pubTime":"2026-09-14 20:43","pubTimestamp":1789389807,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰凌医药(01011)发布公告，经考虑本公司审核委员会的推荐建议，董事会已议决委任国卫会计师事务所有限公司(国卫)为本公司新核数师，以填补大华马施云退任后的临时空缺，自股东于股东特别大会上批准之日起生效，且其任期将直至本公司下一届股东周年大会结束为止。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495868.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01011","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104941084","title":"泰凌医药(01011)拟改聘国卫会计师事务所　估计年度审计费约89.6万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1104941084","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104941084?lang=zh_cn&edition=full","pubTime":"2026-09-14 20:42","pubTimestamp":1789389726,"startTime":"0","endTime":"0","summary":"中国泰凌医药集团有限公司9月14日公告，董事会根据审计委员会建议，议决委任国卫会计师事务所有限公司为公司新核数师，自股东特别大会通过普通决议案之日起生效，任期至下一届股东周年大会结束。该项委任尚待股东特别大会批准。此前，8月28日召开的股东特别大会就委任中正天恒会计师有限公司为核数师的决议案因赞成票不足50%未获通过。董事会于9月10日至11日正式议决委任国卫。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664339840","title":"泰凌医药(01011.HK)发行 8.476亿股认购股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2664339840","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664339840?lang=zh_cn&edition=full","pubTime":"2026-09-04 19:13","pubTimestamp":1788520431,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","01011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143676995","title":"泰凌医药：9月4日配发及发行847,565,892股新股，总金额约3.09亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1143676995","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143676995?lang=zh_cn&edition=full","pubTime":"2026-09-04 19:11","pubTimestamp":1788520313,"startTime":"0","endTime":"0","summary":"泰凌医药于2026年9月4日发布公告，公司根据于2026年8月28日召开的股东特别大会所批准的特定授权，向包括Golden Base Investment Limited、Annie Investment Co., Limited、吴静杰、吴静美、吴铁、黄剑山及杭州艾斯生命科技有限公司在内共7名认购方，配发及发行847,565,892股认购股份。本次发行股份占此前948,997,694股已发行股本的约89.31%。本次新股的发行价为每股0.365港元，发行总金额约3.09亿港元。公告由执行董事吴铁签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"泰凌医药：9月4日配发及发行847,565,892股新股，总金额约3.09亿港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138301308","title":"泰凌医药(01011)完成8.48亿股贷款资本化认购　总股本扩至17.97亿股","url":"https://stock-news.laohu8.com/highlight/detail?id=1138301308","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138301308?lang=zh_cn&edition=full","pubTime":"2026-09-04 19:01","pubTimestamp":1788519708,"startTime":"0","endTime":"0","summary":"中国泰凌医药集团有限公司于2026年9月4日公告，旗下根据特别授权进行的贷款资本化认购事项已完成。公司确认，《认购协议》所载全部先决条件已获达成，认购股份亦于同日正式配发及发行。此次公司按每股0.365港元的认购价，向多名认购人合共发行847,565,892股新股，占经扩大后已发行股本约47.18%。发行完成前，公司已发行股份为948,997,694股；完成后增至1,796,563,586股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137574049","title":"泰凌医药更新8月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1137574049","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137574049?lang=zh_cn&edition=full","pubTime":"2026-09-04 12:30","pubTimestamp":1788496241,"startTime":"0","endTime":"0","summary":"中国泰凌医药集团有限公司于2026年9月4日发布截至2026年8月31日的月度股份变动月报表。公告显示，公司在报告期内并无新增发行、购回或注销股份，整体股本保持稳定。根据月报，泰凌医药本月底普通股已发行股份总数为948,997,694股，与上月底一致；优先股数量亦无变化，均保持在32,500,000股。公告显示，8月份公司无额外发行或库藏股的变动，已发行股份及股本规模与上月底保持一致。公司表示将继续严格依照监管规定履行信息披露义务。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663304006","title":"泰凌医药(01011)：王志强获委任为公司秘书、授权代表及法律程序代理人","url":"https://stock-news.laohu8.com/highlight/detail?id=2663304006","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663304006?lang=zh_cn&edition=full","pubTime":"2026-08-31 21:26","pubTimestamp":1788182784,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰凌医药(01011)发布公告，李怡芳女士已辞任公司的公司秘书、香港联合交易所有限公司证券上市规则第3.05条项下公司的授权代表及上市规则第19.05(2)条及公司条例(香港法例第622章)第16部项下代表公司于香港接收法律程序文件及通知的代理人(法律程序代理人)，自2026年8月31日起生效。王志强先生已获委任为公司的公司秘书、授权代表及法律程序代理人，自2026年8月31日起生效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1489866.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01011","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189733199","title":"泰凌医药（01011）公告人事变动：公司秘书及授权代表8月31日交接","url":"https://stock-news.laohu8.com/highlight/detail?id=1189733199","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1189733199?lang=zh_cn&edition=full","pubTime":"2026-08-31 21:21","pubTimestamp":1788182471,"startTime":"0","endTime":"0","summary":"泰凌医药8月31日在港交所发布公告称，公司董事会已收到李怡芳女士的辞任，李怡芳将自2026年8月31日起不再担任公司秘书、根据上市规则第3.05条的授权代表，以及根据上市规则第19.05条及香港《公司条例》第16部的法律程序代理人。李怡芳确认与董事会无意见分歧，亦无需提请股东及联交所特别关注的事项。董事会感谢李怡芳在任期间的贡献，并对王志强的加入表示欢迎。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663702584","title":"泰凌医药(01011.HK)转仓市值总计2244.08万港元 占比5.91% 从新永安国际证券转出5600万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2663702584","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663702584?lang=zh_cn&edition=full","pubTime":"2026-08-31 08:59","pubTimestamp":1788137995,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["01011","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181584047","title":"泰凌医药(01011)股东特别大会表决结果：认购协议议案获通过，会计师事务所委任议案未获通过","url":"https://stock-news.laohu8.com/highlight/detail?id=1181584047","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181584047?lang=zh_cn&edition=full","pubTime":"2026-08-28 23:02","pubTimestamp":1787929360,"startTime":"0","endTime":"0","summary":"中国泰凌医药集团有限公司2026年8月28日举行股东特别大会并公布表决结果。大会就两项普通决议进行投票，结果如下：。根据股东特别大会公告，需回避投票的股东共持有505,651,342股，因此对此议案有权投票的股份总数为443,346,352股。由于少于50%的有效投票赞成，该议案未获通过。146,520,146股因无效投票未计入第一项议案的表决结果。公司表示，鉴于第二项议案未获通过，将继续物色合适的核数师并于适当时候召开新的股东特别大会审议相关委任事宜。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103953337","title":"泰凌医药（01011）发布2026财年中期业绩：收入增至2,366.5万元 亏损小幅收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=1103953337","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103953337?lang=zh_cn&edition=full","pubTime":"2026-08-20 22:26","pubTimestamp":1787235964,"startTime":"0","endTime":"0","summary":"2026年8月20日，中国泰凌医药集团有限公司公布截至2026年6月30日止六个月未经审核中期业绩。– 收入为2,366.5万元，同比增加97.2%。– 期内亏损1,653.7万元，较上年同期的1,690.6万元减少36.9万元。– 基本及摊薄每股亏损为人民币2.24分，2025年同期为人民币3.03分。以上财务数据均摘自公司于同日发布的《截至2026年6月30日止六个月中期业绩公告》。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01011"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ntpharma.com","stockEarnings":[{"period":"1week","weight":-0.0577},{"period":"1month","weight":-0.4024},{"period":"3month","weight":-0.3467},{"period":"6month","weight":-0.6231},{"period":"1year","weight":-0.6899},{"period":"ytd","weight":-0.7012}],"compareEarnings":[{"period":"1week","weight":0.0087},{"period":"1month","weight":-0.0536},{"period":"3month","weight":-0.1001},{"period":"6month","weight":-0.0963},{"period":"1year","weight":-0.1137},{"period":"ytd","weight":-0.0911}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"中国泰凌医药集团有限公司是一家主要提供医药产品销售及分销服务的投资控股公司。该公司通过两个分部运营业务。数字服务分部主要提供与骨健康知识的市场推广及宣传有关的数字服务。销售代理分部主要提供代理服务为代理客户向外部客户销售医疗及健康相关产品服务。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.003177},{"month":2,"riseRate":0.466667,"avgChangeRate":0.045108},{"month":3,"riseRate":0.4,"avgChangeRate":-0.034671},{"month":4,"riseRate":0.6,"avgChangeRate":0.215361},{"month":5,"riseRate":0.3125,"avgChangeRate":-0.031879},{"month":6,"riseRate":0.3125,"avgChangeRate":-0.023905},{"month":7,"riseRate":0.375,"avgChangeRate":-0.017618},{"month":8,"riseRate":0.3125,"avgChangeRate":-0.053656},{"month":9,"riseRate":0.375,"avgChangeRate":0.027403},{"month":10,"riseRate":0.375,"avgChangeRate":-0.034253},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.071764},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.020063}],"exchange":"SEHK","name":"泰凌医药","nameEN":"NT PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"泰凌医药(01011)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供泰凌医药(01011)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"泰凌医药,01011,泰凌医药股票,泰凌医药股票老虎,泰凌医药股票老虎国际,泰凌医药行情,泰凌医药股票行情,泰凌医药股价,泰凌医药股市,泰凌医药股票价格,泰凌医药股票交易,泰凌医药股票购买,泰凌医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"泰凌医药(01011)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供泰凌医药(01011)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}